Mylan Laboratories 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 8, 2007
MYLAN LABORATORIES INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
(State or other jurisdiction
of Incorporation)
|
|
1-9114
(Commission File
Number)
|
|
25-1211621
(I.R.S. Employer
Identification No.) |
1500 Corporate Drive
Canonsburg, PA 15317
(Address of principal executive offices)
(724) 514-1800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On January 8, 2007, Mylan Laboratories Inc., a Pennsylvania corporation (the Company),
announced the consummation of the acquisition of a controlling stake in Matrix Laboratories Limited
(Matrix), as discussed in Item 2.01 below. Also on January 8, 2007, the Company and Prasad
Nimmagadda, Matrixs former Executive Chairman and current Non-Executive Vice Chairman (Mr.
Prasad), entered into an Executive Employment Agreement (the Employment Agreement) and a
Transition and Succession Agreement (the Transition and Succession Agreement) in connection with
Mr. Prasads employment as an officer of the Company, as well as an Indemnification Agreement (the
Indemnification Agreement) with respect to his service on the Companys Board of Directors.
Employment Agreement
Pursuant to the terms of the Employment Agreement, Mr. Prasad serves as the Companys Head of
Global Strategies in the office of the CEO. The agreement has an initial term of three years and
may be extended or renewed upon mutual agreement of the parties.
Pursuant to the agreement, Mr. Prasad is entitled to an annual base salary of $750,000, and
will be eligible for a discretionary annual bonus equal to 100% of base salary. In addition, Mr.
Prasad was granted stock options to purchase 200,000 shares of the Companys common stock, which
options vest ratably over three years, provided that Mr. Prasad remains employed by the Company on
each vesting date.
Upon Mr. Prasads termination of employment without cause, for good reason (each as
defined in the Employment Agreement), or by reason of death or disability, Mr. Prasad will be
entitled to receive, in addition to his accrued benefits, a lump sum equal to two times (one times,
in the event of Mr. Prasads termination for good reason) the sum of (a) his then-current minimum
annual base salary plus (b) the higher of (i) the average of the annual bonuses paid to Mr. Prasad
in the three fiscal years (or fewer, if applicable) prior to his separation from the Company; or
(ii) the annual bonus applicable for the prior fiscal year. Amounts payable upon death or
incapacity will be reduced by other disability or death benefits that Mr. Prasad or his estate or
beneficiaries are entitled to pursuant to plans or arrangements of the Company. Mr. Prasad will
also be entitled to continuation of employee benefits for a period of two years following
termination of employment with the Company (one year following termination of employment for good
reason). In addition, the options referred to above will vest in full upon Mr. Prasads
termination of employment without cause or for good reason, or if the Employment Agreement is not
renewed. During the term of the Employment Agreement and for a period of two years following
termination of employment for any reason, Mr. Prasad may not engage in activities that are
competitive with the Companys activities and may not solicit the Companys customers or employees.
2
Transition and Succession Agreement
Mr. Prasads Transition and Succession Agreement governs the terms of his employment
commencing on the occurrence of a change of control (as defined in the Transition and Succession
Agreement), and continues for the two year period following which a change of control occurs (as
defined in the Transition and Succession Agreement).
The agreement provides that upon a termination without cause or for good reason or by
reason of Mr. Prasads death or disability (each as defined in the Transition and Succession
Agreement), the Company shall pay to Mr. Prasad a lump sum in cash equal to three times the sum of:
(i) Mr. Prasads then-current annual base salary, plus (ii) an amount equal to the highest bonus
determined under the Employment Agreement or paid to the Mr. Prasad under the Transition and
Succession Agreement (in the case of Mr. Prasads death or disability, reduced by any disability or
death benefits that Mr. Prasad or his estate or beneficiaries are entitled to pursuant to plans or
arrangements of the Company). Mr. Prasad also will be entitled to continuation of employee
benefits for a period of three years following termination of employment with the Company.
Indemnification Agreement
The Indemnification Agreement is substantially similar to those previously entered into by the
Company with its other directors. The Indemnification Agreement provides that the Company will, to
the fullest extent permitted by law, indemnify Mr. Prasad (the Indemnitee) against all expenses,
liability and loss actually incurred in connection with any criminal, civil, administrative or
investigative action, suit or proceeding, whether brought by or in the name of the Company or
otherwise, to which the Indemnitee is a party by reason of his relationship with the Company. In
addition, the Indemnification Agreement provides for the advancement of expenses incurred by the
Indemnitee in connection with any proceeding covered by the Indemnification Agreement.
The foregoing description of the Indemnification Agreement is a general description only and
is qualified in its entirety by reference to the Form of Indemnification Agreement, which is filed
as exhibit 10.31 to the Companys Form 10-Q/A filed for the period ended September 30, 2004, as
filed with the Securities and Exchange Commission (the SEC) effective as of December 3, 2004, and
incorporated herein by reference
Item 2.01. Completion of Acquisition or Disposition of Assets.
As previously announced, on August 28, 2006 the Company entered into a Share Purchase
Agreement (the Share Purchase Agreement) to acquire, through MP Laboratories (Mauritius) Ltd, its
wholly-owned indirect subsidiary, approximately 51.5% of the outstanding share capital of Matrix
Laboratories Limited, a publicly traded Indian company (Matrix), from Prasad Nimmagadda, Prasad
Nimmagadda-Huf, G2 Corporate Services Limited, India Newbridge Coinvestment Limited, India
Newbridge Partners FDI Limited, India Newbridge Investments Limited, Maxwell (Mauritius) Pte.
Limited and Spandana Foundation at a price of Rs. 306 per share.
3
As previously disclosed in the Companys Form 10-Q for
the period ended September 30, 2006, as filed with the SEC on November 3, 2006, in conjunction with
this planned transaction, on August 26, 2006, the Company entered into a foreign exchange forward
contract to purchase Indian rupees with U.S. dollars. The purpose of the forward contract was to
mitigate the risk of foreign currency exposure related to the pending transaction. The value of
the foreign exchange contract fluctuated depending on the value of the U.S. dollar compared to the
Indian rupee. The foreign exchange contract was settled concurrent with our payment of the
purchase price for Matrix outstanding share capital upon the two separate
closings of the transactions under the Share
Purchase Agreement, as described below.
On January 8, 2007, in accordance with the terms of the Share Purchase Agreement, the Company
completed the acquisition of approximately 51.5% of the outstanding share capital of Matrix. As
described in Item 5.02 hereof, effective January 8, 2007, Mr. Prasad has been appointed as a
member of the Board of Directors and as an officer of the Company. As described in Item 1.01
hereof, Mr. Prasad entered into certain agreements with the Company in connection with his
appointment as a member of the Board of Directors and as an officer of the Company.
Also, in accordance with applicable Indian law, the Company previously commenced an open offer
to acquire up to an additional 20% of the outstanding share capital of Matrix (the Public Offer)
from Matrixs shareholders (other than the selling shareholders under the Share Purchase Agreement
and overseas corporate bodies). As previously disclosed, on December 21, 2006, the Company issued
a press release announcing the completion of the Public Offer and its acquisition of 20% of the
outstanding share capital of Matrix, at a price of Rs. 306 per share.
As a result of the two transactions, the Company now owns approximately 71.5% of the
outstanding share capital of Matrix.
On January 8, 2007, the Company and Matrix issued a joint press release announcing the closing
of the Matrix acquisition. A copy of the press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
Item 5.02. Appointment of Directors and Principal Officers.
Effective January 8, 2007, the Board of Directors of the Company appointed Mr. Prasad as a
member of the Board of Directors. The size of the Companys Board was increased from nine (9) to
ten (10) members in connection with the appointment of Mr. Prasad. Also on January 8, 2007, Mr.
Prasad has been appointed as the Head of Global Strategies in the Office of the CEO. Mr. Prasad
has been appointed to serve as a member of the Boards executive committee. Mr. Prasad does not
have any family relationship with any director, executive officer or person nominated or chosen by
us to become a director or executive officer.
4
As previously disclosed, Mr. Prasad and the Company, along with India Newbridge Investments
Limited, India Newbridge Coinvestment Limited, India Newbridge FDI Limited (collectively, the
Newbridge Entities) and Maxwell (Mauritius) Pte. Ltd. (Maxwell) are party to a Shareholders
Agreement, dated as of August 28, 2006 (the Shareholders Agreement), which became effective, or,
in the case of Mr. Prasad, will be effective, upon the closing of the respective previously
announced private sales of the Companys common shares to the Newbridge Entities, Maxwell and Mr.
Prasad. The closing of the private sale of the Companys common shares to the Newbridge entities
and Maxwell was completed on January 8, 2007. In connection with the private sale of the Companys
common shares, the Company and Mr. Prasad entered into a Share Purchase Agreement, dated August 28,
2006 (the Company Share Purchase Agreement), pursuant to which Mr. Prasad has agreed to acquire
from the Company $25 million of the Companys common stock at a price of $20.85 per share, subject to closing of the
Share Purchase Agreement and other customary closing conditions, including certain regulatory
approvals under Indian law. On January 8, 2007, Mr. Prasad assigned his rights and obligations
under the Company Share Purchase Agreement to his affiliate G2 Corporate Services Limited. The
parties anticipate that the completion of the transactions contemplated by the Company Share
Purchase Agreement will occur by the end of January 2007. Pending satisfaction of the closing
conditions to the transaction, a Rupee-equivalent amount to $25 million, to be used for purchase of
the Company shares under the Company Share Purchase Agreement, has been placed by G2 Corporate
Services Limited into an escrow account with Citibank branch in Mumbai, pursuant to an escrow
agreement among the Company, G2 Corporate Services Limited and Citibank N.A.
Pursuant to the Shareholders Agreement, the Company has agreed to use its reasonable best
efforts to cause Mr. Prasad to be appointed as a member of the Companys Board and to cause him to
be nominated or renominated to the Company Board, so long as he owns at least 599,520 shares of the
Companys common stock. A copy of the Shareholders Agreement has been filed as Exhibit 10.3 to the
Companys Form 10-Q for the period ended September 30, 2006, as filed with the SEC on November 3,
2006, and incorporated herein by reference.
As stated above in Item 2.01, on January 8, 2007, the Company issued a press release
announcing, among other things, the appointment of Mr. Prasad as member of the Companys Board and
as an officer of the Company. A copy of the press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
10.1 |
|
|
Executive Employment Agreement dated as of January 8, 2007, by
and between the registrant and Prasad Nimmagadda. |
|
|
|
|
|
|
10.2 |
|
|
Transition and Succession Agreement dated as of January 8,
2007, by and between the registrant and Prasad Nimmagadda. |
|
|
|
|
|
|
99.1 |
|
|
Press release dated January 8, 2007. |
5
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
MYLAN LABORATORIES INC.
|
|
Date: January 9, 2007 |
By: |
/s/ Edward J. Borkowski
|
|
|
|
Edward J. Borkowski |
|
|
|
Chief Financial Officer |
|
6
EXHIBIT INDEX
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
10.1 |
|
|
Executive Employment Agreement dated as of January 8, 2007, by
and between the registrant and Prasad Nimmagadda. |
|
|
|
|
|
|
10.2 |
|
|
Transition and Succession Agreement dated as of January 8,
2007, by and between the registrant and Prasad Nimmagadda. |
|
|
|
|
|
|
99.1 |
|
|
Press release dated January 8, 2007. |
7